Stock vs Stock Comparison

IDEXX Laboratories, Inc. vs Eli Lilly and Company

IDXX wins the Tale of the Tape 5–3.

IDXX$550.82
LLY$1064.15

🏆 Tale of the Tape

53
IDXXLLY
24.6%Profitability (Net Margin)31.7%
41.5xValuation (P/E)39.2x
48.9%Efficiency (ROIC)30.4%
7/9Health (Piotroski F)7/9
20.8Safety (Altman Z)7.8
10.4%Growth (Rev YoY)44.7%
0.96Risk (Sharpe 1Y)0.61
1.09xBalance Sheet (D/E)3.24x
2.32%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.081
252-Day Correlation
0.249
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricIDXXLLY
Market Cap$44.5B$985.4B
P/E Ratio41.5x39.2x
Forward P/E34.1x24.8x
P/B27.98x31.65x
Dividend Yield0.63%
Beta1.570.48

Quantitative Metrics

MetricIDXXLLY
DCF Fair Value$181.78$296.11
DCF Upside-68.3%-68.2%
Piotroski F7/97/9
Altman Z20.807.84
Beneish M-2.46-1.91
FCF Yield2.32%0.68%
Net Debt/EBITDA0.1x1.1x
ROIC48.9%30.4%
WACC15.2%7.8%
ROIC – WACC33.7pp22.5pp
Gross Margin61.8%83.0%
Net Margin24.6%31.7%
Rev Growth YoY10.4%44.7%
Sharpe (1Y)0.960.61
Max Drawdown 3Y
FCF Payout Ratio90%

IDXX Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

IDXX found in:

IHI4.74%
XHE1.57%
VOT1.05%
XLV0.82%
VHT0.72%
VO0.45%
QQQ0.30%
VFQY0.27%
SCHG0.20%
RSP0.19%
IWF0.16%
VUG0.14%
VONG0.14%
ONEO0.14%
QUS0.13%
SPYG0.13%
VFMO0.12%
IVV0.09%
ESGV0.09%
SPLG0.09%
SCHX0.08%
ITOT0.08%
SCHB0.08%
VOO0.07%
VONE0.07%
SPY0.07%
URTH0.06%
SPTM0.06%
VTI0.06%
ACWI0.06%
VT0.04%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

IDXX vs LLY: Head-to-Head Analysis

IDEXX Laboratories, Inc. (IDXX) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, IDXX leads 5–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, IDXX generates a return on invested capital (ROIC) of 48.9% compared to LLY's 30.4%. This suggests IDXX is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between IDXX and LLY is 0.081, indicating low correlation, making them an effective diversification pair in a portfolio context.

IDXX appears in 31 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, IDXX or LLY?

Our quantitative analysis compares IDXX and LLY across nine fundamental dimensions. IDXX wins the Tale of the Tape 5–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are IDXX and LLY correlated?

The 252-day correlation between IDXX and LLY is 0.081. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.